IMpassion131 三期试验:紫杉醇联合或不联合阿替利珠单抗一线治疗晚期三阴性乳腺癌的主要结果
IMpassion131 是一项双盲、安慰剂对照、随机 III 期试验,评估阿替利珠单抗联合紫杉醇对比安慰剂联合紫杉醇一线治疗不可切除局部晚期/转移性三阴性乳腺癌。结果显示,在 PD-L1 阳性人群中,联合阿替利珠单抗未改善研究者评估的无进展生存期(HR 0.82,95%CI 0.60-1.12,P=0.20),总生存也无差异(HR 1.11,95%CI 0.76-1.64)。
要点
- PD-L1 阳性人群中,阿替利珠单抗联合紫杉醇未显著改善 PFS(HR 0.82,P=0.20)。
- PD-L1 阳性人群中,联合组总生存无获益(HR 1.11,95%CI 0.76-1.64)。
- 安全性特征与各研究药物的已知效应一致。
核心结论
- 在晚期三阴性乳腺癌一线治疗中,阿替利珠单抗联合紫杉醇对比紫杉醇单药未改善 PFS 或 OS。
研究设计与样本
- 双盲、安慰剂对照、随机 III 期试验,共随机 651 例患者,按 2:1 分配至阿替利珠单抗 840 mg 或安慰剂(第 1、15 天),均联合紫杉醇 90 mg/m2(第 1、8、15 天),每 28 天为一周期。
- 分层因素包括肿瘤 PD-L1 状态、既往紫杉烷治疗、肝转移和地理区域;主要终点为研究者评估的 PFS,先在 PD-L1 阳性人群(免疫细胞表达≥1%,VENTANA PD-L1 SP142 检测)中检验,再在 ITT 人群中检验。
主要发现
- PD-L1 阳性人群中,阿替利珠单抗联合紫杉醇组 vs 安慰剂联合紫杉醇组的中位 PFS 为 6.0 个月 vs 5.7 个月(HR 0.82,95%CI 0.60-1.12,P=0.20)。
- PD-L1 阳性人群中,联合组未确认的最佳总缓解率为 63% vs 55%,中位缓解持续时间为 7.2 个月 vs 5.5 个月。
- PD-L1 阳性人群中,最终 OS 分析显示两组无差异(HR 1.11,95%CI 0.76-1.64;中位 OS 22.1 个月 vs 28.3 个月)。
- ITT 人群结果与 PD-L1 阳性人群一致。
临床怎么用
- 本试验结果不支持在晚期三阴性乳腺癌一线治疗中常规联合阿替利珠单抗与紫杉醇。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab-paclitaxel in aTNBC. PATIENTS AND METHODS: Eligible patients [no prior systemic therapy or ≥12 months since (neo)adjuvant chemotherapy] were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m2 (days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. Stratification factors were tumour PD-L1 status, prior taxane, liver metastases and geographical region. The primary endpoint was investigator-assessed PFS, tested hierarchically first in the PD-L1-positive [immune cell expression ≥1%, VENTANA PD-L1 (SP142) assay] population, and then in the ITT population. OS was a secondary endpoint. RESULTS: Of 651 randomised patients, 45% had PD-L1-positive aTNBC. At the primary PFS analysis, adding atezolizumab to paclitaxel did not improve investigator-assessed PFS in the PD-L1-positive population [hazard ratio (HR) 0.82, 95% confidence interval (CI) 0.60-1.12; P = 0.20; median PFS 6.0 months with atezolizumab-paclitaxel versus 5.7 months with placebo-paclitaxel]. In the PD-L1-positive population, atezolizumab-paclitaxel was associated with more favourable unconfirmed best overall response rate (63% versus 55% with placebo-paclitaxel) and median duration of response (7.2 versus 5.5 months, respectively). Final OS results showed no difference between arms (HR 1.11, 95% CI 0.76-1.64; median 22.1 months with atezolizumab-paclitaxel versus 28.3 months with placebo-paclitaxel in the PD-L1-positive population). Results in the ITT population were consistent with the PD-L1-positive population. The safety profile was consistent with known effects of each study drug. CONCLUSION: Combining atezolizumab with paclitaxel did not improve PFS or OS versus paclitaxel alone. CLINICALTRIALS.GOV: NCT03125902.
引用
- Miles D, Gligorov J, André F, et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021. PMID: 34219000. doi:10.1016/j.annonc.2021.05.801
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。